Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants
NCT ID: NCT03893032
Last Updated: 2019-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
80 participants
INTERVENTIONAL
2019-07-17
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Modafinil 200mg
single, 200 mg dose of modafinil
Modafinil 200mg
single 200 mg dose
mixed amphetamine salts
single 10 mg dose of mixed amphetamine salts
mixed amphetamine salts
single 10 mg dose
placebo
placebo
Placebo
single oral-administration placebo tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modafinil 200mg
single 200 mg dose
mixed amphetamine salts
single 10 mg dose
Placebo
single oral-administration placebo tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have normal hearing, vision or corrected to normal vision, and cognitive function as determined by self-report
* Must have obtained at minimum 6 hours of sleep prior to all testing sessions, as assessed by actigraphy data and self-report. Should the actiwatch malfunction, reliance on self-report will suffice. If the subject does not meet this requirement, he will be asked to reschedule
* Must have refrained from consumption of stimulants (including caffeine) and over the counter medications which may induce drowsiness for a minimum of 16 hours prior to each test session, and nicotine, 8 hours, prior to all testing sessions, assessed by self-report.
Exclusion Criteria
* No current medical conditions or medications affecting cognitive function or attention as determined by screening by study physician or medical practitioner
* Current or recent use (as determined by study physician or medical practitioner) of medications that may interact with the test articles. Determined by self-report and exclusion at the discretion of the study physician or medical practitioner.
* Any history of any attention deficit condition requiring medication. A history of any attention deficit condition with medication is disqualifying as the potential interactions with testing are unknown and would therefore produce a potential source of confounding or bias into the results of the study.
* Any history of psychological/psychiatric disorder.
* Any history of addiction or substance abuse as assessed through self-report.
* Any history of metabolic disorder such as dysthyriodism.
* Any history of significant cardiovascular disease or hypertension.
* Any history of hepatic or renal disorder.
* Females will be excluded given that the drugs administered could potentially negatively impact the very early stages of pregnancy.
* Any ingestion of substances that may interact with the test articles or potentially skew the results within the last 16 hours prior to testing including over-the-counter medications, supplements, etc. (see attached list to be reviewed with subject).
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Army Aeromedical Research Laboratory
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amanda Kelley
Research Psychologist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
US Army Aeromedical Research Laboratory
Fort Rucker, Alabama, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Amanda M Kelley, PhD
Role: primary
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USAARL 2018-007; IRB M-10746
Identifier Type: -
Identifier Source: org_study_id